Biomerica, Inc. (NASDAQ:BMRA – Get Free Report)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.97 and traded as low as $0.70. Biomerica shares last traded at $0.72, with a volume of 59,331 shares trading hands.
Biomerica Stock Down 1.2 %
The company’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $0.96. The stock has a market capitalization of $11.99 million, a price-to-earnings ratio of -1.93 and a beta of -1.04.
Biomerica (NASDAQ:BMRA – Get Free Report) last released its quarterly earnings results on Friday, April 12th. The company reported ($0.11) EPS for the quarter. Biomerica had a negative return on equity of 64.00% and a negative net margin of 117.46%. The business had revenue of $1.02 million for the quarter.
Hedge Funds Weigh In On Biomerica
About Biomerica
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Further Reading
- Five stocks we like better than Biomerica
- How to buy stock: A step-by-step guide for beginners
- High-Yield Texas Instruments Could Hit New Highs Soon
- Basic Materials Stocks Investing
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.